5‐Year clinical follow‐up of the COBRA (complex coronary bifurcation lesions: Randomized comparison of a strategy using a dedicated self‐expanding biolimus A9‐eluting stent vs. a culotte strategy using everolimus‐eluting stents) study

Bennett, Johan; Adriaenssens, Tom; McCutcheon, Keir; Dens, Joseph; Desmet, Walter; Sinnaeve, Peter; Vrolix, Mathias; Dubois, Christophe

doi:10.1002/ccd.27597

Cited by 8 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Data from another population showed even better results for Axxess at five years. 13 The long-term data for Tryton at two years showed the MACE rate of 23.8%, the cardiac death rate of 4.4%, the MI rate of 10.2% and the TLR rate of 9.2%. 14 In case of Stentys at 5 years, the target vessel failure was 22.8%, but a high rate of stent thrombosis was observed (4.5%).…”

Section: Discussionmentioning

confidence: 98%

“…Additionally, when analysing data from other dedicated bifurcation stents, the Axxess stent's long‐term results disclosed the following 3‐year rates: MACE – 19.5%, cardiac death – 2.0%, MI – 7.4% and clinically driven TLR – 10.1% 12 . Data from another population showed even better results for Axxess at five years 13 . The long‐term data for Tryton at two years showed the MACE rate of 23.8%, the cardiac death rate of 4.4%, the MI rate of 10.2% and the TLR rate of 9.2% 14 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

6‐year results of BiOSS stents in coronary bifurcation treatment

Gil

Witkowski

Formuszewicz

et al. 2021

Eur J Clin Investigation

View full text Add to dashboard Cite

Coronary bifurcation stenting strategies continue to be refined, developed and tested, mainly due to the wide variation in bifurcation anatomy. 1 Dedicated bifurcation stents are still one of the vivid options. In the recent European Bifurcation Club white paper on stenting techniques, the new classification MADS-2 included formally dedicated bifurcation stents as a fully fledged treatment option, including BiOSS stents. 2

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

6‐year results of BiOSS stents in coronary bifurcation treatment

Gil

Witkowski

Formuszewicz

et al. 2021

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Furthermore, upon examining data from other dedicated bifurcation stents, the long-term data (over 3 years) of the Axxess stent revealed a MACE rate of 19.5%, a cardiac death rate of 2.0%, an MI rate of 7.4%, and a clinically driven TLR rate of 10.1% [28]. Findings from a separate cohort demonstrated even more favorable outcomes for the Axxess stent at 5 years [29]. At 2 years, the extended data for Tryton revealed a MACE rate of 23.8%, a cardiac death rate of 4.4%, an MI rate of 10.2%, and a TLR rate of 9.2% [30].…”

Section: Discussionmentioning

confidence: 99%

The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results

Gil,

Kern,

Bojko

et al. 2024

Biomedicines

View full text Add to dashboard Cite

This multicenter, randomized study aimed to compare the sirolimus-eluting BiOSS LIM C dedicated coronary bifurcation stent with second-generation -limus drug-eluting stents (rDESs) in the treatment of non-left main (non-LM) coronary bifurcation. The deployment of a single stent in the main vessel–main branch across a side branch was the default strategy in all patients. The primary endpoint was the rate of major cardiovascular events (cardiac death, myocardial infarction, and target lesion revascularization) at 48 months. We enrolled 230 patients, allocating 116 patients to the BiOSS LIM C group and 114 patients to the rDES group. Most procedures were elective (BiOSS vs. rDES: 48.3% vs. 59.6%, p = 0.09) and performed in bifurcations within the left anterior descending/diagonal branch (BiOSS vs. rDES: 51.7% vs. 61.4%, p = 0.15). At 48 months, there were no statistically significant differences between the BiOSS and rDES groups in terms of major adverse cardiovascular events (MACE), cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR) as follows: MACEs—18.1% vs. 14.9%, HR 1.36, 95% CI 0.62–2.22, and p = 0.33; cardiac death—4.3% vs. 3.5%, HR 1.23, 95% CI 0.33–4.56, and p = 0.75; MI—2.6% vs. 3.5%, HR 0.73, 95% CI 0.17–3.23, and p = 0.68; and TLR—11.2% vs. 7.9%, HR 1.66, 95% CI 0.75–3.71, and p = 0.21. The implantation success rate of the BiOSS LIM C stent was very high, and the cumulative MACE rates were promising. The POLBOS 3 trial sets an important benchmark for treating non-LM coronary bifurcations (ClinicalTrials.gov NCT03548272).

show abstract

“…It is implanted in the proximal MV with its distal end aligned to the carina, allowing easy access to both the distal MV and the SB[ 149 ]. In the COBRA study, Axxess with two biolimus-eluting stents (in the distal MV and the SB) was compared to the culotte stenting technique with two everolimus-eluting stents and found no difference in stent coverage at 9 mo and similar favorable clinical outcomes at 5 years[ 150 ].…”

Section: Dedicated Bifurcation Stentsmentioning

confidence: 99%

Fundamentals of percutaneous coronary bifurcation interventions

Kırat¹

2022

WJC

View full text Add to dashboard Cite

Coronary bifurcation lesions (CBLs) account for 15%-20% of all percutaneous coronary interventions. The complex nature of these lesions is responsible for poorer procedural, early and late outcomes. This complex lesion subset has received great attention in the interventional cardiac community, and multiple stenting techniques have been developed. Of these, the provisional stenting technique is most often the default strategy; however, the elective double stenting (EDS) technique is preferred in certain subsets of complex CBLs. The double kissing crush technique may be the preferred EDS technique because of its efficacy and safety in comparative trials; however, this technique consists of many steps and requires training. Many new methods have recently been added to the EDS techniques to provide better stent scaffolding and to reduce early and late adverse outcomes. Intravascular imaging is necessary to determine the interventional strategy and postinterventional results. This review discusses the basic concepts, contemporary percutaneous interventional technical approaches, new methods, and controversial treatment issues of CBLs.

show abstract

5‐Year clinical follow‐up of the COBRA (complex coronary bifurcation lesions: Randomized comparison of a strategy using a dedicated self‐expanding biolimus A9‐eluting stent vs. a culotte strategy using everolimus‐eluting stents) study

Abstract: Compared with culotte stenting with Xience, complex coronary bifurcation stenting using a dedicated strategy combining the Axxess and Biomatrix stents results in similar stent strut coverage at 9 months, and excellent clinical outcomes at 5 years.

Cited by 8 publications

References 16 publications

6‐year results of BiOSS stents in coronary bifurcation treatment

6‐year results of BiOSS stents in coronary bifurcation treatment

The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results

Fundamentals of percutaneous coronary bifurcation interventions

Contact Info

Product

Resources

About